Delivery Order SPE2DB24D2003-SPE2DB25FXGN2
- Not listed
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Dupixent 300 mg/2 ml pens, a medication used to treat certain medical conditions. The contract has a ceiling value of $22,307.39 and is a firm fixed-price, non-set-aside contract with an ultimate completion date of April 22, 2025. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Dupixent 300 mg/2 ml pens, a medication used to treat certain medical conditions. The contract has a ceiling value of $75,545.53 and is a firm fixed-price, non-set-aside contract with a performance period ending on May 2, 2025. AmerisourceBergen Drug Corp holds a significant...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Dupixent 300 mg/2 ml pens, a medication used to treat certain medical conditions. The contract has a firm fixed price and a ceiling value of $48,421.41. It is not a set-aside contract, indicating open competition. The contract has an ultimate completion date of April 23, 2025. AmerisourceBergen Drug Corp holds a...
- This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,799.49, is for the supply of Dupixent 300 mg/2 ml pens, a medication used to treat certain medical conditions. The contract is a firm fixed-price delivery order with an ultimate completion date of April 24, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Dupixent 300 mg/2 ml pen with a ceiling value of $111,731.27. The contract is a firm fixed-price, non-set-aside award with a completion date of July 16, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Dupixent 300 mg/2 ml pens, a medication used to treat certain medical conditions. The contract has a ceiling value of $11,894.76 and a performance period extending through May 1, 2025. The contract is a firm fixed-price delivery order, and there is no set-aside designation, indicating open competition....
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Dupixent 300 mg/2 ml pens, a medication used to treat certain medical conditions. The contract has a ceiling value of $16,943.62 and is a firm fixed-price, non-set-aside contract with a performance period ending on May 6, 2025. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Dupixent 300 mg/2 ml pens, a medication used to treat certain medical conditions. The contract has a ceiling value of $14,676.26 and a performance period ending on April 28, 2025. This contract is not set aside for any specific business type. AmerisourceBergen Drug Corp holds a...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Dupixent 300 mg/2 ml pens. The contract has a firm fixed price, with a ceiling value of $40,776.90, and runs through March 10, 2025. The contract is not set aside for any specific business category. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999, which...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Dupixent 300 mg/2 ml pens. The contract has a ceiling value of $11,497.38 and an ultimate completion date of September 12, 2024. The contract is a firm-fixed-price delivery order, with no set-aside designation. AmerisourceBergen, through its extensive supply chain network, will provide these critical prescription medications to...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXGN2Delivery Order
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Dupixent 300 mg/2 ml pens, a medication used to treat certain medical conditions. The contract has a ceiling value of $8,767.72 and is a firm fixed-price, non-set-aside contract with an ultimate completion date of April 4, 2025. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which serves as a comprehensive global pharmaceutical support vehicle through December 2026. This contract allows for multiple delivery orders across different therapeutic categories, positioning AmerisourceBergen as a critical vendor in supporting federal medical procurement needs, particularly for military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.8k | 4/3/25 |